Form 4 for CRL Charles River Laboratories
Accepted 2023-07-05 00:00:00 ET · period of report 2023-07-03 · accession 0001127602-23-019952 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-07-05 | 2023-07-03 | CRL | MACKAY MARTIN | Dir | A - Grant | $0.00 | +95 | 11.6K | +0.8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-07-03 | A | A | 95 | $0.00 | 11,600 | D | — | — | (F1) The grant was made in lieu of director service fees for the term commencing May 9, 2023. The restricted stock units vest the earlier of July 3, 2024 and the business day prior to the Company's next annual meeting of shareholders. |